We are live on ! Find out more
BOLD

Audentes Therapeutics, Inc
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

Back to rankings

114 hedge funds and large institutions have $1.43B invested in Audentes Therapeutics, Inc in 2018 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 44 increasing their positions, 30 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 30

39% more call options, than puts

Call options by funds: $2.85M | Put options by funds: $2.05M

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

4% more capital invested

Capital invested by funds: $1.37B → $1.43B (+$56.1M)

7% less funds holding

Funds holding: 123 → 114 (-9)

45% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 20

Holders
114
Holders Change
-9
Holders Change %
-7.32%
% of All Funds
2.61%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
11
Increased
44
Reduced
30
Closed
20
Calls
$2.85M
Puts
$2.05M
Net Calls
+$808K
Net Calls Change
+$2.5M

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$42.1M
2
NC
Nexthera Capital
New York
+$11.2M
3
UBS AM
UBS AM
Illinois
+$9.44M
4
AllianceBernstein
AllianceBernstein
Tennessee
+$7.08M
5
CC
Casdin Capital
New York
+$6.52M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$25.2M
2
DM
Deerfield Management
New York
-$20.7M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$16.2M
4
O
OrbiMed
New York
-$16.2M
5
Millennium Management
Millennium Management
New York
-$12.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
26
Foresite Capital Management III
California
$12.5M – – –
EAM
27
Eventide Asset Management
Massachusetts
$10.9M – – –
UBS AM
28
UBS AM
Illinois
$10M +$9.44M +253,334 New
AG
29
Artal Group
Luxembourg
$9.9M +$522K +14,000 +6%
WM
30
WS Management
Florida
$9.54M – – –
CS
31
Candriam SCA
Luxembourg
$9.45M +$6.31M +169,300 +244%
OM
32
Opaleye Management
Massachusetts
$8.91M +$1.3M +35,000 +18%
Goldman Sachs
33
Goldman Sachs
New York
$7.79M +$795K +21,328 +12%
PAMU
34
Pictet Asset Management (UK)
United Kingdom
$6.88M +$6.48M +173,829 New
Charles Schwab
35
Charles Schwab
California
$6.76M +$3.84M +103,073 +152%
Dimensional Fund Advisors
36
Dimensional Fund Advisors
Texas
$6.71M +$6.32M +169,445 New
Invesco
37
Invesco
Georgia
$6.38M +$1.52M +40,906 +34%
Macquarie Group
38
Macquarie Group
Australia
$5.15M +$876K +23,500 +22%
Morgan Stanley
39
Morgan Stanley
New York
$5.1M -$3M -80,573 -38%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$5.06M +$2.87K +77 +0.1%
CAM
41
Cormorant Asset Management
Massachusetts
$4.95M -$7.38M -197,945 -61%
Federated Hermes
42
Federated Hermes
Pennsylvania
$4.86M -$386K -10,355 -8%
Deutsche Bank
43
Deutsche Bank
Germany
$4.86M +$1.67M +44,732 +57%
SFM
44
Sphera Funds Management
Israel
$4.75M +$4.47M +120,000 New
JP Morgan Chase
45
JP Morgan Chase
New York
$4.64M +$124K +3,331 +3%
OCM
46
Osterweis Capital Management
California
$4.58M +$110K +2,950 +3%
CI
47
Cowen Inc
New York
$3.96M +$746K +20,000 +25%
Axa
48
Axa
France
$3.06M – – –
Allianz Asset Management
49
Allianz Asset Management
Germany
$2.96M +$193K +5,168 +7%
TCIM
50
TIAA CREF Investment Management
New York
$2.68M -$198K -5,314 -7%
1
2
3 4 5

BOLD Hedge Fund Activity: Q3 2018 in Review

114 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q3 2018, worth a combined $1.43B — up 4.1% from $1.37B a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of BOLD and 11 opened new positions — a net loss of 9 holders — while 30 trimmed existing stakes and 44 added.

The largest buyer was PFM Health Sciences, adding an estimated $42.1M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $25.2M sold.

  • 114 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q3 2018, down from 123 in Q2 2018.
  • Funds reported $1.43B of Audentes Therapeutics, Inc stock for Q3 2018, up 4.1% quarter-over-quarter.
  • 11 funds opened new Audentes Therapeutics, Inc positions in Q3 2018 and 20 closed out, a net change of -9 holders.
  • The largest Audentes Therapeutics, Inc buyer in Q3 2018 was PFM Health Sciences, an estimated $42.1M added.
  • The largest Audentes Therapeutics, Inc seller in Q3 2018 was Perceptive Advisors, an estimated $25.2M sold.

Based on aggregated 13F filings for Q3 2018.